On January 15, Horizon Technology Finance committed up to $50 million in a venture loan facility to Pelthos Therapeutics, aiming to advance the biotech’s clinical and preclinical oncology programs. This deal represents one of Horizon’s largest single financings in recent quarters and underscores its focus on funding high-growth life sciences ventures.

Horizon is expected to report Q4 results with consensus estimates of $0.30 in earnings per share on $24.66 million of revenue for the quarter ended December 2025. Analysts have revised the EPS forecast downward by 3.5% over the last 30 days, reflecting cautious outlooks on portfolio yield and credit spreads.

Operating within the Financial – SBIC & Commercial industry, Horizon’s venture loan to Pelthos enhances its exposure to higher-risk, higher-return assets. The company’s credit quality metrics and yield profile will be closely watched on the upcoming earnings call, as market volatility and interest rate trends may influence funding costs and profit margins.